Lantheus expands its oncology portfolio in an all-cash transaction, adding Octevy, a registrational-stage positron emission tomography (PET) diagnostic agent for certain neuroendocrine tumors (NETs).

When I was supposed to be writing this editorial, I instead was watching the funeral of former US president James Earl Carter of Georgia. The eulogy and speeches by family members and politicians were ...